TORONTO, ON-DNAstack, a Toronto based company, has landed a National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) investment to support development of its cloud-based genomics software platform.
The funding will go towards a project that hopes to deliver DNAstack’s cloud platform to Canadian genomics researchers, as well as provide cost optimizations and geographic data sovereignty for sensitive personal health information. The 12-month project could position DNAstack as a national hub in genomics data storage and bioinformatics.
“We are thrilled with the vision that NRC-IRAP has shown with this investment into our company to build enterprise-grade infrastructure to support genomics activities in Canada and internationally,” Dr. Marc Fiume, CEO of DNAstack said.
Dr. Fiume adds Canada lacks solutions for genomics data analysis that leverage economies of scale that are provided by modern commercial cloud computing platforms.
“This technology will give scientists access to massive computing power to accelerate breakthroughs in understanding the causes of genetic diseases like cancer and autism.”
DNAstack is already working with leading research and clinical labs at SickKids and Mount Sinai hospitals in Toronto. It is developing its platform in partnership with the Global Alliance for Genomics & Health, which sets global standards for handling genomics and clinical information. Moreover, DNAstack is building its solution to comply with security and privacy policies that often restrict storage of this kind of data within national borders. The opportunity to empower secure, scalable computation in Canada is new, as only recently have commercial cloud providers set up data centres on Canadian soil.
“Genetic diseases know no boundaries” said Dr. Fiume. “We are excited to bring powerful and responsible genomics data analysis practices into new geographies, furthering our mission to promote the development of a global network of connected genomics and health information to accelerate discoveries and the delivery of precision medicine.”